Citable filing context
CVS's research view summarizes recent SEC filing context, starting with management_change from Aug 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 17, 2026 | management_change | Teresa Heitsenrether was appointed to the CVS Health Board of Directors, and Larry M. Robbins resigned. |
| Aug 5, 2026 | earnings | CVS Health reported Q2 2026 revenue of $106.1 billion and raised its full-year 2026 adjusted EPS guidance. |
| May 18, 2026 | management_change | CVS stockholders elected 13 nominees to the Board of Directors at the 2026 Annual Meeting. |
| Aug 5, 2026 | Guidance: adjusted_eps | 7.90 to 8.10 |
| Aug 5, 2026 | Guidance: cash_flow_from_operations | 11500.00 to not reported |
| Aug 5, 2026 | Guidance: gaap_diluted_eps | 6.84 to 7.04 |
| Aug 5, 2026 | mda_quarterly | CVS Health reported strong financial performance for the second quarter of 2026, with total revenues rising 7.3% to $106.1 billion and operating income surging 97.5% to $4.7 billion. This growth was bolstered by improved performance across all segments and the absence of significant legacy litigation charges that impacted the prior-year period. The Health Care Benefits segment saw adjusted operating income rise 85.5%, driven by favorable performance in the Government business and the absence of prior-year premium deficiency reserves. However, the company faces ongoing pressure from elevated medical utilization, which could impact future margins. The Health Services segment, anchored by CVS Caremark, benefited from brand inflation and pharmacy drug mix, though it continues to navigate competitive pricing pressures and regulatory scrutiny regarding PBM transparency and 340B drug pricing. The Pharmacy & Consumer Wellness segment reported a 10.2% increase in adjusted operating income, supported by core pharmacy strength and volume from Rite Aid asset acquisitions, despite headwinds from generic drug introductions and shifting consumer spending toward value-oriented retailers. CVS maintains a solid liquidity position with $11.3 billion in cash and remains committed to its capital allocation strategy, including consistent dividend payments, while monitoring potential supply chain disruptions and evolving federal and state regulations. |
| May 6, 2026 | mda_quarterly | CVS Health reported Q1 2026 total revenues of $100.4 billion, a 6.2% increase year-over-year, with net income rising 65.4% to $2.9 billion. This growth was significantly aided by the absence of prior-year legacy litigation and Accountable Care asset charges. The Health Care Benefits segment improved its Medical Benefit Ratio to 84.6%, driven by strong Government business performance, despite exiting the individual exchange market. Health Services revenue grew 11% to $48.2 billion due to brand inflation and drug mix, though adjusted operating income declined 7.1% amid pharmacy client price improvements. In the Pharmacy & Consumer Wellness segment, revenues remained flat; a 6.8% increase in same-store prescription volume and Rite Aid asset acquisitions were offset by reimbursement pressures and weather disruptions, leading to an 8.8% drop in adjusted operating income. Critical risks include persistently elevated medical utilization, increasing regulatory scrutiny of PBM activities, and pressure from pharmaceutical manufacturers regarding rebate calculations. Macroeconomic concerns include inflation, tariffs, and a consumer shift toward value retailers. The company maintains $9.5 billion in cash, though Fitch and S&P maintain a negative outlook on its investment-grade debt. |
Source: SEC EDGAR filing text and events; period Aug 17, 2026; filed Aug 17, 2026.
CVS company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.